Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model.

Tsuji T, Ozasa H, Aoki W, Aburaya S, Funazo T, Furugaki K, Yoshimura Y, Ajimizu H, Okutani R, Yasuda Y, Nomizo T, Uemasu K, Hasegawa K, Yoshida H, Yagi Y, Nagai H, Sakamori Y, Ueda M, Hirai T, Kim YH.

Mol Cancer Res. 2019 Jan;17(1):212-224. doi: 10.1158/1541-7786.MCR-18-0325. Epub 2018 Aug 31.

PMID:
30171175
2.

Nivolumab in non-small-cell lung cancer with EGFR mutation.

Yoshida H, Kim YH, Ozasa H, Nagai H, Sakamori Y, Tsuji T, Nomizo T, Yasuda Y, Funazo T, Hirai T.

Ann Oncol. 2018 Mar 1;29(3):777-778. doi: 10.1093/annonc/mdx745. No abstract available.

PMID:
29161357
3.

Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer.

Tsuji T, Sakamori Y, Ozasa H, Yagi Y, Ajimizu H, Yasuda Y, Funazo T, Nomizo T, Yoshida H, Nagai H, Maeno K, Oguri T, Hirai T, Kim YH.

Oncotarget. 2017 May 16;8(42):71805-71816. doi: 10.18632/oncotarget.17895. eCollection 2017 Sep 22.

4.

Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease.

Yasuda Y, Nomizo T, Ozasa H, Funazo T, Tsuji T, Yoshida H, Sakamori Y, Nagai H, Handa T, Kubo T, Kim YH.

Mol Clin Oncol. 2017 Oct;7(4):677-680. doi: 10.3892/mco.2017.1373. Epub 2017 Aug 11.

5.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Treated with Nivolumab.

Funazo T, Nomizo T, Kim YH.

J Thorac Oncol. 2017 Sep;12(9):e140-e141. doi: 10.1016/j.jtho.2017.04.027. No abstract available.

6.

Successful Treatment with Alectinib for Choroidal Metastasis in Anaplastic Lymphoma Kinase Rearranged Non-small Cell Lung Cancer.

Funazo T, Morita K, Ikegami N, Konishi C, Nakao S, Ariyasu R, Taki M, Nakagawa K, Hwang MH, Yoshimura C, Wakayama T, Nishizaka Y.

Intern Med. 2017 Sep 1;56(17):2317-2320. doi: 10.2169/internalmedicine.8488-16. Epub 2017 Aug 10.

7.

Successful oral desensitization with crizotinib after crizotinib-induced hepatitis in an anaplastic lymphoma kinase-rearranged non-small-cell lung cancer patient: A case report.

Yasuda Y, Nishikawa Y, Sakamori Y, Terao M, Hashimoto K, Funazo T, Nomizo T, Tsuji T, Yoshida H, Nagai H, Ozasa H, Hirai T, Kim YH.

Mol Clin Oncol. 2017 Aug;7(2):295-297. doi: 10.3892/mco.2017.1310. Epub 2017 Jun 29.

8.

EGFR T790M Detection in Circulating Tumor DNA from Non-small Cell Lung Cancer Patients Using the PNA-LNA Clamp Method.

Yoshida H, Kim YH, Ozasa H, Nagai H, Sakamori Y, Tsuji T, Nomizo T, Funazo T, Yasuda Y, Hirai T.

Anticancer Res. 2017 May;37(5):2721-2725.

PMID:
28476851
9.

Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients.

Nomizo T, Ozasa H, Tsuji T, Funazo T, Yasuda Y, Yoshida H, Yagi Y, Sakamori Y, Nagai H, Hirai T, Kim YH.

Sci Rep. 2017 Mar 23;7:45124. doi: 10.1038/srep45124.

10.

Varicella Reinfection with Unilateral Varicella Pneumonia.

Ariyasu R, Nakagawa K, Ikegami N, Konishi C, Nakao S, Funazo T, Taki M, Morita K, Hwang MH, Yoshimura C, Wakayama T, Nishizaka Y.

Intern Med. 2016;55(21):3143-3145. Epub 2016 Nov 1.

11.

Prolonged disturbance of consciousness caused by severe hypophosphatemia: a report of two cases.

Murakami T, Yoshida M, Funazo T, Matsuda Y, Matsuo K, Nambu T, Yonemitsu S, Muro S, Oki S.

Intern Med. 2014;53(19):2227-32.

Supplemental Content

Loading ...
Support Center